Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes

AIM: Multiple studies support the efficacy of combining a glucagon‐like peptide 1 receptor agonist (GLP‐1RA) with basal insulin in people with type 2 diabetes inadequately controlled on dual/triple oral therapy. Fixed‐ratio combinations of basal insulin + GLP‐1RA represent a further advance to facil...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrannini, Ele, Niemoeller, Elisabeth, Dex, Terry, Servera, Soraly, Mari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314929/
https://www.ncbi.nlm.nih.gov/pubmed/35257461
http://dx.doi.org/10.1111/dom.14688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314929/
https://www.ncbi.nlm.nih.gov/pubmed/35257461
http://dx.doi.org/10.1111/dom.14688

Ejemplares similares